ReviewFrontiers in immunology2021
Immunological Considerations for
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- T cell responses in repeated controlled human schistosome infection compared to natural exposure.Nature communications · 2025Trial
- Host immune network-guided reverse vaccinology approach for prioritizing candidate antigens in Schistosoma japonicum-associated liver fibrosis.PLoS neglected tropical diseases · 2026Article
- Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations.NPJ vaccines · 2026Article
- Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis.PLoS neglected tropical diseases · 2026Review
- The human immunome in the post-schistosomiasis mass drug administration era.PLoS neglected tropical diseases · 2026Review
- Mass drug administration of praziquantel lowers the susceptibility of school-aged children toFrontiers in immunology · 2026Article
- In silico design of a multi-epitope pan vaccine targeting Schistosoma species.Genomics & informatics · 2025Article
- Structure-Activity Relationship and Target Investigation of Thiophen-2-yl-Pyrimidines againstbioRxiv : the preprint server for biology · 2025Article
- Vaccine value profile for schistosomiasis.Vaccine · 2025Article
- Praziquantel Pretreatment ReducesTropical medicine and infectious disease · 2025Article
- Schistosomiasis: cercarial finding and recognizing of human hosts as a prerequisite of invasion.Clinical microbiology reviews · 2025Review
- Effect of Praziquantel on Preventing Delayed Infection ofMicroorganisms · 2024Article
- Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.Immunity, inflammation and disease · 2024Review
- Transmission-Blocking Vaccines against Schistosomiasis Japonica.International journal of molecular sciences · 2024Review
- Systems and computational analysis of gene expression datasets reveals GRB-2 suppression as an acute immunomodulatory response against enteric infections in endemic settings.Frontiers in immunology · 2024Article
- Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.PLoS neglected tropical diseases · 2023Article
- A Critical Review on Human Malaria and Schistosomiasis Vaccines: Current State, Recent Advancements, and Developments.Vaccines · 2023Review
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Despite mass drug administration programmes with praziquantel, the prevalence of schistosomiasis remains high. A vaccine is urgently needed to control transmission of this debilitating disease. As some promising schistosomiasis vaccine candidates are moving through pre-clinical and clinical testing, we review the immunological challenges that these vaccine candidates may encounter in transitioning through the clinical trial phases in endemic settings. Prior exposure of the target population to schistosomes and other infections may impact vaccine response and efficacy and therefore requires considerable attention. Schistosomes are known for their potential to induce T-reg/IL-10 mediated immune suppression in populations which are chronically infected. Moreover, endemicity of schistosomiasis is focal whereby target and trial populations may exhibit several degrees of prior exposure as well as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.